Development of a new hydrogen peroxide-based vaccine platform

104Citations
Citations of this article
113Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Safe and effective vaccines are crucial for maintaining public health and reducing the global burden of infectious disease. Here we introduce a new vaccine platform that uses hydrogen peroxide (H 2O 2) to inactivate viruses for vaccine production. H 2O 2 rapidly inactivates both RNA and DNA viruses with minimal damage to antigenic structure or immunogenicity and is a highly effective method when compared with conventional vaccine inactivation approaches such as formaldehyde or β-propiolactone. Mice immunized with H 2O 2-inactivated lymphocytic choriomeningitis virus (LCMV) generated cytolytic, multifunctional virus-specific CD8 + T cells that conferred protection against chronic LCMV infection. Likewise, mice vaccinated with H 2O 2-inactivated vaccinia virus or H 2O 2-inactivated West Nile virus showed high virus-specific neutralizing antibody titers and were fully protected against lethal challenge. Together, these studies demonstrate that H 2O 2-based vaccines are highly immunogenic, provide protection against a range of viral pathogens in mice and represent a promising new approach to future vaccine development. © 2012 Nature America, Inc. All rights reserved.

Cite

CITATION STYLE

APA

Amanna, I. J., Raué, H. P., & Slifka, M. K. (2012). Development of a new hydrogen peroxide-based vaccine platform. Nature Medicine, 18(6), 974–979. https://doi.org/10.1038/nm.2763

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free